James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the ...
Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...
Let's catch up on the latest news from the stock market. From significant investments to major deals, fund raising and appointments, here’s a quick look at which stocks will be in focus in today's ...